Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mayo Clinic Laboratories, |
RCV000660613 | SCV000782730 | uncertain significance | Combined oxidative phosphorylation defect type 15 | 2017-08-25 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002530580 | SCV003556395 | uncertain significance | Inborn genetic diseases | 2022-06-21 | criteria provided, single submitter | clinical testing | The c.19C>G (p.R7G) alteration is located in exon 1 (coding exon 1) of the MTFMT gene. This alteration results from a C to G substitution at nucleotide position 19, causing the arginine (R) at amino acid position 7 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |